The elevation of AST and ALT level represents the prevailing abnormalities in NAFLD patients.[2] There was more extensive reduction in ALT level than that in AST after SIL treatments, because the original level of ALT was far higher than the AST leaving the more for ALT to decline accordingly. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.